FDA
-
-
-
-
-
-
-
Harmony Biosciences forecasts WAKIX revenue to exceed $1 billion in 2026
-
-
-
-
-
-
-
Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M
-
-
-
-
-
-
-
Harmony Biosciences (HRMY) Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205
-
-
-
-
-
-
-
Harmony Biosciences (HRMY) Appoints Adam Zaeske as Chief Commercial Officer
-
-
-
-
-
-
-
Harmony Biosciences (HRMY) Provides Update on the Status of the Supplemental New Drug Application for Pitolisant
-
-
-
-
-
-
-
Harmony Biosciences (HRMY) Highlights New Data, Robust Late-stage Pipeline With Near-term Value Creation Opportunities And Its Bold New Vision At Investor Day
-
-
-
-
-
-
-
HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT)
-
328,148 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

